Opioid Use Disorder: Signs, Symptoms, Effects, and Treatment Options

Opioid use disorder (OUD) is a chronic, treatable medical condition marked by compulsive opioid use despite mounting harm, and recovery is possible with evidence-based care.

The disorder can follow prescription pain treatment, illicit drug use, or a mix of both. It affects people across every age, race, and income level.

OUD changes how the brain processes reward, pain, and stress by flooding mu-opioid receptors with activity that the body eventually cannot regulate on its own. Over time, tolerance grows, withdrawal appears, and cravings override judgment.

Modern treatment combines medication, therapy, and structured outpatient programming so patients can stabilize without stepping away from daily life.

Key Takeaways

• OUD is a medical diagnosis, not a character flaw: the DSM-5 recognizes 11 criteria that measure severity as mild, moderate, or severe.
• Overdose is a mass-scale crisis: the CDC estimated about 81,083 opioid-involved overdose deaths in the United States in 2023, with illicitly manufactured fentanyl driving the majority.
• Fentanyl is 50 to 100 times more potent than morphine: even trace amounts in counterfeit pills or mixed powders can be fatal.
• Medication for opioid use disorder (MOUD) saves lives: methadone, buprenorphine, and naltrexone are FDA-approved and cut overdose mortality roughly in half.
• Naloxone (Narcan) reverses overdose: a nasal spray version has been available over the counter since 2023.

What Opioids Are and How They Act on the Brain

Opioids are a class of pain-relieving compounds that bind to mu-opioid receptors in the brain, spinal cord, and gut to blunt pain and trigger dopamine release. They include natural alkaloids, semi-synthetic derivatives, and fully synthetic laboratory compounds.

Natural Opiates

• Morphine: the reference opioid, derived from the opium poppy and used for severe pain.
• Codeine: a weaker natural opiate often combined with acetaminophen for cough and moderate pain.

Semi-synthetic Opioids

• Oxycodone: sold as OxyContin, Percocet, and Roxicodone for moderate to severe pain.
• Hydrocodone: sold as Vicodin and Norco, historically one of the most prescribed analgesics in the country.
• Hydromorphone: sold as Dilaudid, a potent inpatient analgesic.
• Heroin: an illegal semi-synthetic derived from morphine, typically injected, smoked, or snorted.

Fully Synthetic Opioids

• Fentanyl: a laboratory-made opioid 50 to 100 times more potent than morphine and the leading driver of overdose deaths.
• Methadone: a long-acting full agonist used in opioid treatment programs (OTPs) and for chronic pain.
• Tramadol: a weaker synthetic with both opioid and serotonergic activity.

Prescription versus Illicit Supply

• Prescription origin: many cases of OUD begin with medically supervised pain care that escalates over weeks or months.
• Illicit origin: heroin, counterfeit pills pressed with fentanyl, and fentanyl-laced stimulants drive most overdose deaths today, according to the DEA National Drug Threat Assessment.

Signs and Symptoms of Opioid Use Disorder

Signs of opioid addiction combine physical, behavioral, and psychological changes that persist despite clear harm. The DSM-5 diagnoses OUD when at least 2 of 11 criteria occur within a 12-month period.

Behavioral Signs

• Loss of control: using larger amounts or for longer periods than intended.
• Unsuccessful cutback attempts: repeated efforts to reduce use that fail within days.
• Time consumed by use: hours spent obtaining, using, or recovering from opioids.
• Role failure: missed work shifts, skipped classes, or neglected childcare duties.
• Risky use: taking opioids while driving, mixing with alcohol or benzodiazepines, or sharing injection equipment.

Physical Signs

• Tolerance: needing more of the drug to reach the same effect.
• Withdrawal: predictable symptoms when doses are missed or reduced.
• Constricted pupils: pinpoint pupils during active intoxication.
• Sedation cycles: nodding off mid-conversation or mid-task.
• Constipation and appetite loss: gut motility slows dramatically under chronic opioid activity.

Psychological and Social Signs

• Cravings: intense urges that intrude on thoughts during the day.
• Continued use despite consequences: legal issues, medical complications, or family breakdown do not deter use.
• Withdrawal from life: loss of interest in hobbies, relationships, or goals that once mattered.

Causes and Risk Factors

No single cause creates OUD; it emerges from a blend of biological, psychological, and environmental pressures. Understanding these factors helps families move beyond blame and toward treatment.

Biological Risk Factors

• Genetics: first-degree relatives with any substance use disorder carry an elevated risk.
• Neurobiology: repeated opioid exposure remodels dopamine and stress circuits, making abstinence physically painful.
• Co-occurring conditions: chronic pain, depression, PTSD, and anxiety all raise vulnerability.

Environmental Risk Factors

• Access and exposure: leftover prescriptions at home are a common gateway.
• Adverse childhood experiences (ACEs): abuse, neglect, and household instability raise long-term risk.
• Peer and community factors: neighborhoods with heavy illicit supply normalize use and overdose exposure.
• Early initiation: starting any substance use in adolescence is linked to greater risk of severe OUD.

Short-term and Long-term Effects

Opioids produce immediate effects within minutes, while repeated use causes progressive damage across body systems. Both acute and chronic effects can be life-threatening.

Short-term Effects

• Euphoria and sedation: the dopamine surge that drives repeat use.
• Respiratory depression: slowed breathing that can progress to overdose.
• Nausea and vomiting: especially with initial use or a dose increase.
• Itching and flushing: histamine release from mu-receptor activity.
• Impaired judgment: slowed thinking and reaction time that raises injury risk.

Long-term Effects

• Hormonal disruption: suppressed testosterone, menstrual changes, and fertility problems.
• Cardiovascular and infectious disease: endocarditis, abscesses, hepatitis C, and HIV among people who inject.
• Cognitive and mood changes: persistent anhedonia, depression, and sleep disruption.
• Gastrointestinal harm: severe chronic constipation and bowel dysfunction.
• Dental and nutritional decline: especially with heroin and counterfeit pill use.

Overdose Recognition and Naloxone Reversal

Opioid overdose is a medical emergency caused by respiratory depression that, without quick reversal, leads to brain injury and death within minutes. Any bystander can act.

How to Recognize an Overdose

• Unresponsiveness: the person does not wake to a loud voice or a sternal rub.
• Slowed or stopped breathing: fewer than 10 breaths per minute, gurgling, or no chest rise.
• Pinpoint pupils: tiny, constricted pupils during the event.
• Blue or gray lips, nails, or skin: cyanosis from low oxygen.
• Limp body and cold, clammy skin: late-stage signs before cardiac arrest.

Emergency Warning: Fentanyl Contamination

Assume any non-prescribed pill or powder may contain fentanyl. Fentanyl is 50 to 100 times more potent than morphine, and counterfeit Xanax, Percocet, or Adderall tablets pressed with fentanyl are now common, according to the FDA and DEA. Never use alone, and always carry naloxone.

How to respond with naloxone

• Call 911 immediately: emergency medical response is required even after reversal.
• Give naloxone (Narcan) nasal spray: 1 full spray into one nostril, repeat every 2 to 3 minutes if no response.
• Start rescue breathing: tilt the head back, lift the chin, and give one breath every 5 seconds if trained.
• Place in recovery position: lay the person on their side once breathing returns to prevent choking.
• Stay until help arrives: naloxone wears off in 30 to 90 minutes and re-overdose is possible.

The CDC confirms that over-the-counter naloxone nasal spray has been available since 2023, and nalmefene (Opvee) is now approved as a longer-acting reversal option for synthetic opioid exposures.

Opioid withdrawal symptoms and timeline

Opioid withdrawal symptoms are rarely fatal in healthy adults, yet they are intensely uncomfortable and a major driver of relapse. Timing depends on which opioid was used.

Timeline by opioid class

• Short-acting opioids: heroin, oxycodone, and hydrocodone withdrawal usually begins 6 to 30 hours after last use.
• Long-acting opioids: methadone withdrawal typically begins 30 to 72 hours after last use.
• Peak symptoms: 36 to 72 hours into acute withdrawal.
• Acute phase: 7 to 10 days of the most intense symptoms.
• Post-acute withdrawal syndrome (PAWS): mood, sleep, and craving disturbances that can last weeks to months.

Common withdrawal symptoms

• Flu-like symptoms: lacrimation, rhinorrhea, yawning, and sweating.
• Muscle effects: piloerection (goosebumps), myalgia, and restless legs.
• Gastrointestinal symptoms: nausea, vomiting, abdominal cramping, and diarrhea.
• Autonomic signs: dilated pupils, elevated heart rate, and blood pressure spikes.
• Psychological symptoms: anxiety, agitation, insomnia, and strong cravings.

Medically supervised withdrawal

Clinicians use buprenorphine, methadone tapers, and supportive agents to ease symptoms. Lofexidine (Lucemyra), a non-opioid alpha-2 agonist, was approved by the FDA in 2018 specifically to reduce withdrawal symptoms in adults.

Medication for opioid use disorder (MAT)

MAT for opioid use disorder, also called medication for opioid use disorder (MOUD), pairs FDA-approved medications with counseling to normalize brain chemistry, block cravings, and reduce overdose risk. Three medications form the foundation of care.

Methadone

• Mechanism: long-acting full mu-opioid agonist that prevents withdrawal and blunts cravings.
• Setting: dispensed only through federally certified opioid treatment programs (OTPs).
• Best for: patients with severe OUD, long use histories, or prior unsuccessful trials of partial agonists.

Buprenorphine, Suboxone, Subutex, and Sublocade

• Mechanism: partial mu-opioid agonist with a ceiling effect that lowers respiratory depression risk.
• Forms: Subutex (buprenorphine alone), Suboxone (buprenorphine plus naloxone film or tablet), and Sublocade (monthly extended-release injection).
• Access: prescribed in office-based settings since the X-waiver was removed by the Mainstreaming Addiction Treatment (MAT) Act, effective January 2023.
• Best for: patients seeking flexible, office-based care alongside work, school, or family duties.

Naltrexone and Vivitrol

• Mechanism: full mu-opioid antagonist that blocks opioid effects entirely.
• Forms: daily oral tablet or Vivitrol monthly intramuscular injection.
• Requirement: patients must be fully detoxified, usually 7 to 14 days opioid-free, before induction.
• Best for: patients who want a non-opioid medication or who are leaving structured settings.

NIDA research shows MOUD roughly halves all-cause mortality and overdose deaths compared with behavioral treatment alone.

Behavioral therapies for OUD

Medication alone is powerful, and pairing it with structured therapy addresses the thoughts, triggers, and relationships that sustain use. Evidence-based approaches include several proven models.

Core evidence-based therapies

• Cognitive behavioral therapy (CBT) identifies high-risk thoughts and builds coping skills for cravings and stress.
• Contingency management provides tangible rewards for negative drug screens and treatment attendance.
• Community reinforcement approach (CRA) reshapes daily life so sober activities become more rewarding than use.
• Motivational interviewing resolves ambivalence and strengthens commitment to change.
• Family therapy rebuilds communication, trust, and healthy roles at home.
• Relapse prevention and aftercare program maps personal warning signs and creates written response plans.

Before exploring program-specific care, it helps to understand how outpatient levels of care work together and how patients move between them based on clinical need.

Treatment at Right Choice Recovery

Right Choice Recovery offers structured outpatient care for OUD in New Jersey, combining MOUD access, individual therapy, and group programming. Each level meets different clinical and scheduling needs.

Partial care program

• Intensity: 5 days per week, up to 6 hours per day of clinical programming.
• Focus: early stabilization, medication management, trauma-informed groups, and relapse prevention.
• Who benefits: patients stepping down from detox or inpatient care, or those needing intensive daytime structure benefit from partial care.

Intensive outpatient program (IOP)

• Intensity: 3 to 5 sessions per week, typically 3 hours per session.
• Focus: skills groups, individual therapy, MAT coordination, and family sessions.
• Who benefits: patients balancing treatment with work, school, or parenting while maintaining strong support in intensive outpatient program.

Outpatient program

• Intensity: 1 to 2 sessions per week of therapy and medication follow-up during outpatient program.
• Focus: long-term recovery maintenance, ongoing MOUD support, and relapse response planning.
• Who benefits: patients with stable housing, employment, and a maturing support network.

Same-day assessments

Right Choice Recovery offers same-day clinical assessments so patients can begin treatment quickly, verify insurance coverage, and meet the clinical team.

Frequently asked questions

What is the difference between opioid dependence and opioid use disorder?

Opioid dependence is a physical state marked by tolerance and withdrawal that can occur even with medically supervised use. OUD is a DSM-5 diagnosis that also requires loss of control, cravings, or continued use despite harm. A person can be dependent without having OUD, and treatment decisions depend on the full clinical picture.

Is medication-assisted treatment just swapping one drug for another?

No. Methadone and buprenorphine stabilize brain chemistry without producing the euphoric spikes that drive compulsive use, and naltrexone contains no opioid activity at all. Research cited by NIDA shows MOUD lowers overdose death rates, improves retention in care, and supports long-term recovery when combined with therapy.

How long does opioid withdrawal last?

Acute withdrawal from short-acting opioids usually begins within 6 to 30 hours, peaks at 36 to 72 hours, and eases over 7 to 10 days. Methadone withdrawal starts later and can last 10 to 20 days. Post-acute symptoms such as sleep disturbance and cravings may persist for weeks or months.

Can I take Suboxone or Sublocade and still work?

Yes. Buprenorphine products, including Suboxone film, Subutex tablets, and the monthly Sublocade injection are designed for office-based care. Most patients drive, work, parent, and study while stabilized on the medication, which is part of why the MAT Act expanded access in 2023.

What should I do if I find someone unresponsive after using opioids?

Call 911 right away, give naloxone (Narcan) nasal spray, and begin rescue breathing if trained. Place the person on their side once breathing resumes and stay with them because naloxone wears off in 30 to 90 minutes. Do not delay care even if the person wakes up.

Does insurance cover opioid use disorder treatment?

Most commercial plans, Medicaid, and Medicare cover medically necessary OUD care, including MOUD and outpatient therapy, under federal parity law. Right Choice Recovery verifies benefits at no cost and explains any out-of-pocket estimates before services begin.

If you or a loved one is struggling with opioids, Right Choice Recovery can help you start outpatient treatment in New Jersey this week. Our licensed clinicians build a plan around your medical needs, your schedule, and your long-term recovery goals so you can heal without pausing the rest of your life.

References

• Centers for Disease Control and Prevention. (2024). Drug overdose deaths in the United States, 2003–2023 (NCHS Data Brief). U.S. Department of Health and Human Services. https://www.cdc.gov/
• Centers for Disease Control and Prevention. (2024). Treatment of opioid use disorder. https://www.cdc.gov/overdose-prevention/treatment/opioid-use-disorder.html
• National Institute on Drug Abuse. (2025). Medications for opioid use disorder. National Institutes of Health. https://nida.nih.gov/research-topics/medications-opioid-use-disorder
• Substance Abuse and Mental Health Services Administration. (2024). Medications for substance use disorders. U.S. Department of Health and Human Services. https://www.samhsa.gov/
• U.S. Food and Drug Administration. (2023). FDA approves first over-the-counter naloxone nasal spray. https://www.fda.gov/
• U.S. Food and Drug Administration. (2018). FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults. https://www.fda.gov/
• Drug Enforcement Administration. (2024). National Drug Threat Assessment. U.S. Department of Justice. https://www.dea.gov/
• American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). https://www.psychiatry.org/patients-families/opioid-use-disorder